Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Protease resistant" patented technology

Studies indicate that protease resistance is least likely to develop when these agents are given in combination with two nucleosides. Protease inhibitors should always be administered at optimal therapeutic doses; suboptimal doses of these drugs merely promote the development of high-level protease resistance.

Recombinant CCN domain proteins and fusion proteins

ActiveUS12606602B2Antibody mimetics/scaffoldsPeptide/protein ingredientsThrombospondinCCN Family Proteins
The present invention relates to recombinant proteins having an amino acid sequence corresponding to or related to the thrombospondin type 1 repeat homology domain of a member of the CCN family proteins and the use thereof. Furthermore, the present invention relates to fusion proteins comprising an amino acid sequence corresponding to or related to the thrombospondin type 1 repeat homology domain of a member of the CCN family proteins combined with a fusion partner and optionally a linker region. Also, novel protease resistant Fc-fragments are disclosed herein.
Owner:UNIV OSLO HF

Lactobacillus johnsonii producing novel class iii bacteriocins, engineered bacteria and application thereof

The present application relates to a lactobacillus johnsonii producing a novel class III bacteriocin, an engineered bacterium and application thereof, and belongs to the technical field of microorganisms. Lactobacillus johnsonii The JLJ071 strain of the lactobacillus johnsonii is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.34541. The bacteriocin amino acid sequence is shown in Seq ID No.1. The expressed novel class III bacteriocin has good bactericidal activity on listeria monocytogenes and salmonella pullorum, and has good characteristics such as acid resistance, high temperature resistance and protease resistance, and has a good application prospect in feed additives.
Owner:BEIJING ACADEMY OF AGRICULTURE & FORESTRY SCIENCES

Modified catalytically inactive forms of chymotrypsin like elastase 2a (cela2a) and uses thereof

The present application provides modified Chymotrypsin-like ELAstase 2A (CELA2A) proteins such as catalytically inactivate and protease resistant CELA2A proteins. Also provided herein are the uses of the CELA2A proteins for preserving pancreatic islet size, number as well as enhancing insulin secreting and insulin signaling and for the treatment of diabetes, pancreatitis and other related diseases.
Owner:YALE UNIVERSITY

Cosmetic application of cyclic polypeptide and supramolecular liposome product of cyclic polypeptide

The invention provides a cosmetic application of a cyclic polypeptide, the cyclic polypeptide is H-Cys-Tyr-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro-Cys-Lys (Met-Pro-D-Ph-Arg-D-Trp-Ph-Lys-Pro-Val-PEG5CH2CO)-NH2 (1, 13 disulfide bond cyclization), and the cyclic polypeptide is used for preparing a cosmetic skin care product which is used for breaking sensitive circulation and controlling hyperpigmentation and has the effects of resisting allergy and whitening at the same time. The cyclic polypeptide is prepared into a product through a supramolecular liposome infiltration promotion technology, is resistant to protease degradation and takes effect for a long time. According to the cosmetic application of the annular polypeptide and the supramolecular liposome product of the annular polypeptide, multiple key receptors can be targeted at the same time, sensitive circulation can be broken through, chromatosis can be controlled, meanwhile, the anti-allergic and whitening effects are achieved, and the multiple skin problems faced by people with sensitive skin can be solved in cooperation with an efficient delivery system.
Owner:CHENGDU SUNNA BIOPEPTIDE TECH CO LTD +1

Novel IIa bacteriocin-producing pediococcus pentosaceus and application thereof

The invention provides a Pediococcus pentosaceus ZPP083 strain, which is preserved in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CGMCC No.31944. The Pediococcus pentosaceus ZPP083 strain has the advantages that the Pediococcus pentosaceus ZPP083 strain can be used for preparing the Pediococcus pentosaceus ZPP083 strain; the pediococcus pentosaceus provided by the invention has a relatively strong antibacterial effect, can produce novel IIa bacteriocin, and has the characteristics of acid resistance, high temperature resistance, protease resistance and the like. Genetically engineered bacteria are constructed by using the bacteriocin, and the expression quantity is improved.
Owner:BEIJING ACADEMY OF AGRICULTURE & FORESTRY SCIENCES